These inaccuracies in the real entire world underscore the urgency to create much more sensitive HER2 diagnostic assays to make sure that eligible patients aren't deprived of effective therapies. In BC, pCR right after NACT is a surrogate endpoint for a long-phrase clinical final result, which could be less appropriate https://www.directivepublications.org/journal-of-clinical-breast-cancer/